Laboratoires du Centre: Correction made to the company’s consolidation financial report for the first quarter of 2022 completed at Mops

Provided by: Center Laboratories, Inc.

SEQ_NO

1

announcement date

2022/06/08

Announcement time

18:53:44

Matter

 Correction made on the Company's Consolidation
Financial Report for the Q1 2022 filled to the Mops

Date of events

2022/06/08

What item it responds to

paragraph 53

Statement

1.Date of occurrence of the event:2022/06/08
2.Company name:Center Laboratories, Inc.
3.Relationship to the Company (please enter "head
  office" or  "subsidiaries"):Head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
Newly added notes to the Administrative Expenses from Consolidated of
Comprehensive Income Statement of the Company's Q1 2022 Consolidated
Financial Report
6.Information items/ statements to be corrected:
On P7 Consolidated of Comprehensive Income Statement and P35 item 六.15
Provision on Debts
7.Amounts/ contents/ number of page to be corrected:
P7 Administrative Expenses Unannotated
8.Amounts/ contents/ number of page after correction:
(1) Added notes 六.15 to P7 Administrative Expenses
(2) Newly added illustration on P35 item 六.15 Provision on Debts
9.Countermeasures:
In Q1 2022, the market price of listed OTC stocks which held by Bioengine
Capital Inc. fell. According to the management agreement, recalculating
the performance bonus that was book as a debt reserve; simultaneously,
reduced the amount of debt reserve and write down 175,7000 thousand of
Administrative Expense (for Performance Bonus). Consequently, lead to
a negative Administrative Expense under Operating Expense on Q1 2022
Consolidated Income Statement
10.Any other matters that need to be specified:None.